1. Scrip
  2. >>R&D

Pfizer Executive On Paxlovid’s Development And Design Journey

 
• By Anju Ghangurde

Senior Pfizer executive outlines the accelerated development approach for Paxlovid, one that took just 17 months, but was done without cutting any corners for safety and also sought to guard against resistance from the design perspective.

paxlovid
Paxlovid's Journey From Synthesis To EUA • Source: Alamy

A senior Pfizer Inc. executive outlined, at a recent summit, some of the defining aspects of COVID-19 treatment Paxlovid’s (nirmatrelvir and ritonavir) development journey from first synthesis to first emergency use authorization (EUA). It was strikingly fast – speed with urgency and without cutting any corners for safety, as the executive put it.

Addressing the Organization of Pharmaceutical Producers of India (OPPI) summit, Pfizer’s senior vice president and chief scientific officer, bacterial vaccines and hospital, Dr Annaliesa Anderson, indicated that the oral antiviral...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.